Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

1,189 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Hypoxia--a key regulatory factor in tumour growth.
Harris AL. Harris AL. Nat Rev Cancer. 2002 Jan;2(1):38-47. doi: 10.1038/nrc704. Nat Rev Cancer. 2002. PMID: 11902584 Review.
A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis.
Williams KJ, Telfer BA, Airley RE, Peters HP, Sheridan MR, van der Kogel AJ, Harris AL, Stratford IJ. Williams KJ, et al. Oncogene. 2002 Jan 10;21(2):282-90. doi: 10.1038/sj.onc.1205047. Oncogene. 2002. PMID: 11803471
Metabolic changes detected by in vivo magnetic resonance studies of HEPA-1 wild-type tumors and tumors deficient in hypoxia-inducible factor-1beta (HIF-1beta): evidence of an anabolic role for the HIF-1 pathway.
Griffiths JR, McSheehy PM, Robinson SP, Troy H, Chung YL, Leek RD, Williams KJ, Stratford IJ, Harris AL, Stubbs M. Griffiths JR, et al. Cancer Res. 2002 Feb 1;62(3):688-95. Cancer Res. 2002. PMID: 11830521
Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer.
Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, van Trappen P, Cox G, Harris AL, Jackson DG. Beasley NJ, et al. Cancer Res. 2002 Mar 1;62(5):1315-20. Cancer Res. 2002. PMID: 11888898
Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer.
Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, Bicknell R, Taylor M, Gatter KC, Harris AL. Leek RD, et al. Cancer Res. 2002 Mar 1;62(5):1326-9. Cancer Res. 2002. PMID: 11888900
Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients.
Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL. Beasley NJ, et al. Cancer Res. 2002 May 1;62(9):2493-7. Cancer Res. 2002. PMID: 11980639
Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL. Turner KJ, et al. Cancer Res. 2002 May 15;62(10):2957-61. Cancer Res. 2002. PMID: 12019178
Angiogenesis in bladder cancer--prognostic marker and target for future therapy.
Streeter EH, Harris AL. Streeter EH, et al. Surg Oncol. 2002 Jun;11(1-2):85-100. doi: 10.1016/s0960-7404(02)00013-0. Surg Oncol. 2002. PMID: 12031871 Review.
HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron.
Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ, Maxwell PH. Mandriota SJ, et al. Cancer Cell. 2002 Jun;1(5):459-68. doi: 10.1016/s1535-6108(02)00071-5. Cancer Cell. 2002. PMID: 12124175
Drug inhibition of angiogenesis.
Madhusudan S, Harris AL. Madhusudan S, et al. Curr Opin Pharmacol. 2002 Aug;2(4):403-14. doi: 10.1016/s1471-4892(02)00184-4. Curr Opin Pharmacol. 2002. PMID: 12127873 Review.
1,189 results
Jump to page